Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(24):1822-1831; doi:10.1093/jnci/94.24.1822
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 24, 1822-1831, December 18, 2002
© 2002 Oxford University Press

EDITORIAL

Body Surface Area in Dosing Anticancer Agents: Scratch the Surface!

Antonius A. Miller

Correspondence to: Antonius A. Miller, M.D., Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd., Winston-Salem, NC 27157 (e-mail: aamiller@wfubmc.edu).

The first 10% of the full text of this article appears below.

Grochow et al. (1) questioned the use of body surface area in dose normalization more than a decade ago in this Journal. In this issue, Baker et al. (2) retrospectively assessed the pharmacokinetics of 33 investigational agents tested in phase I trials during the past decade as a function of body surface area in 1650 adult cancer patients. Based on their findings, they recommend that the practice of calculating starting doses on the basis of body surface area in phase I trials should be abandoned. Historically, we have initiated phase I dosing based on body surface area and then retained the practice, carrying it forward through phase II and III studies and ultimately to Food and Drug Administration labeling. Should . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. A. Traina, M. Theodoulou, K. Feigin, S. Patil, K. L. Tan, C. Edwards, U. Dugan, L. Norton, and C. Hudis
Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1797 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. H.J. Mathijssen, F. A. de Jong, W. J. Loos, J. M. van der Bol, J. Verweij, and A. Sparreboom
Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?
Oncologist, August 1, 2007; 12(8): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Salinger, J. S. McCune, A. G. Ren, D. D. Shen, J. T. Slattery, B. Phillips, G. B. McDonald, and P. Vicini
Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach.
Clin. Cancer Res., August 15, 2006; 12(16): 4888 - 4898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Miller, G. L. Rosner, M. J. Egorin, D. Hollis, S. M. Lichtman, M. J. Ratain, and for the Cancer and Leukemia Group B
Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid Tumors: Cancer and Leukemia Group B Study 9763
Clin. Cancer Res., December 15, 2004; 10(24): 8325 - 8331.
[Abstract] [Full Text] [PDF]